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respond to treatment in the initial 12 weem model cycle. Patients could relapse or 
continue to respond wto treatment in subsequent cycles. Based on pooled efﬁcacy data 
the initial reponse probability for IVIG used in the model was 0.47(95% C.I. 0.36, 
0.58). Based on a published study, the 12 week proability of relaspe used in the model 
was 0.06 (95% C.I. 0.02,0.14). Non-responding IVIG patients were assumed to be 
switched to corticosteroids. Patients on corticosteroids were at risk of a number of 
adverse events (fracture, diabetes, glaucoma, cataract, serious infection) each cycle. 
RESULTS: Over the 5 year time horizon the model estimated the incrmetnal costs and 
QALYs of IVIG treatment compared to corticosteroid treatment to be $105,356 and 
0.188 repsectively. The incremental cost per QALY of IVIG was estaimated to be 
$551,031. The cost per QALY of IVIG was very sensitive to the assumption on fre-
quency and dosing of maintenance IVIG treatment. CONCLUSIONS: Based on 
common willingness to pay thresholds, IVIG might not be perceived as a cost effective 
treatment for CIDP.
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OBJECTIVES: Conduct an economic evaluation comparing treatment costs between 
5% and 10% Intravenous Immunoglobulin (IVIG) preparations. METHODS: A cost-
minimization analysis (CMA) was performed to compare treatment costs between ﬁve 
5% (including one lyophilized product) and one 10% IVIG preparations, as there are 
no differences in outcomes achieved between different IVIG preparations. The CMA 
was done using a societal perspective and cost included both health care costs as well 
as caregiver costs. More speciﬁcally, the following costs were considered in the model: 
drug costs, facility costs, pharmacy and nursing costs and productivity costs. Other 
data included in the model were obtained from the products’ prescribing information. 
One adult patient (65 kg) and one pediatric patient (25 kg) receiving a dose of 0.4 g/kg 
were modeled. RESULTS: Even though equal cost per gram was assumed across all 
the IVIG products considered in the model, total drug cost was higher for one of the 
5% product because of the limited choice in vial sizes for this particular product. Only 
the lyophilized product incurred pharmacy costs for reconstitution ($15.0). Infusion 
time was shortened by 51 minutes with the 10% product (2.0 h compared to the 5% 
products (2.9 h), saving approximately $21.4 per infusion. For the adult patient, 
nursing costs were higher for the 5% products as more vials were required during the 
infusion (4 to 5 vials for 5% vs. 3 for 10%). On average, the use of a 10% preparation 
saved $65.2 per dose for the adult patient and $32.7 per dose for the pediatric patient. 
Assuming a dosing frequency of 3 weeks, yearly savings could range between $522.2 
and $3.072.2 in adults and $486.8 and $831.6 in children. CONCLUSIONS: The 
availability of a 10% IVIG preparation could generate substantial savings compared 
to 5% preparations.
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THALIDOMIDE PLUS MELPHALAN AND PREDNISONE FOR 
AUSTRALIAN PATIENTS NEWLY DIAGNOSED WITH MULTIPLE 
MYELOMA IS COST-EFFECTIVE WHEN COMPARED WITH MELPHALAN 
AND PREDNISONE ALONE
De Abreu Lourenco R, Colman S, Lee C
Covance Pty Ltd, North Ryde, NSW, Australia
OBJECTIVES: Thalidomide is an immonumodulatory drug that has been shown in a 
phase III clinical trial to be effective when used in combination with melphalan and 
prednisone (MPT) in patients newly diagnosed with multiple myeloma who are unable 
to undergo stem cell transplant (SCT) or high-dose chemotherapy (HDC). As part of 
an application to the Pharmaceutical Beneﬁts Advisory Committee (PBAC) in Australia 
we assessed whether such use is cost-effective when compared with MP alone, the 
current standard of care. METHODS: Data on the comparative efﬁcacy of MPT versus 
MP alone were sourced from a completed international phase III study. The results 
from that study showed a statistically signiﬁcant difference in median survival of 1.53 
years (p  0.0006) in favour of MPT. We applied a digitising program to the published 
Kaplan-Meier survival curves in order to estimate the mean survival (area under the 
curve) and extrapolate the results to a lifetime horizon. These data were incorporated 
into a cost-effectiveness analysis taking the perspective of the Australian health care 
system. Outcomes were assessed as quality adjusted life years gained (QALYG), based 
on applying published utility values to the extrapolated survival data. The costs of the 
primary drug therapies (MPT or MP), associated medical services, and the treatment 
of thalidomide related adverse events were all included. Costs and beneﬁts were dis-
counted at 5% per annum, and costs were stated in A$ at 2008 prices. RESULTS: 
The modelled analysis estimated an incremental gain in average survival of 1.47 years. 
This translated into 1.14 QALYGs once the utility values were applied. The associated 
average incremental cost was AUS$23,953. The resulting cost per QALYG was 
A$20,998. CONCLUSIONS: This analysis resulted in a positive recommendation 
from the PBAC to fund thalidomide for the treatment of patients newly diagnosed 
with multiple myeloma.
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OBJECTIVES: This study assesses the cost-effectiveness of Intradiscal electrothermal 
therapy (IDET) relative to femoral ring allografts (FRA), a form of spinal fusion, for 
discogenic back pain. Spinal fusion is an established surgical treatment; IDET is less 
invasive and potentially less costly. McKenna (2005) reported an RCT comparing 
FRA and titanium cage (TC). Based on this trial, Freeman (2007) demonstrated the 
relative cost-effectiveness of FRA. The present study used the same FRA cohort for 
evaluating the cost-effectiveness of IDET vs. FRA. METHODS: Patient-level data on 
resource use up to 24 months and SF-36 (measured pre-operatively and at 6, 12, 24 
months) were available for all 37 FRA patients of McKenna (2005) trial. Comparable 
data were collected prospectively on 85 patients treated with IDET at Queen’s Medical 
Centre, Nottingham. Data variables were matched between the two patient groups. 
Utility scores were produced from SF-36 by using Brazier (2004) algorithm. Differen-
tial costs and utilities, together with 95% conﬁdence intervals, were estimated using 
bias corrected and accelerated bootstrapping. RESULTS: There were no signiﬁcant 
differences between the groups in age, gender or SF-36 domain scores, except physical 
function (p  0.004) and mental health (p  0.021), both lower in the FRA group. 
Baseline utility scores were lower in the FRA group (0.48 vs. 0.52, p  0.03).On the 
central assumptions, the expected cost per patient was lower with IDET by £3713 
(95% CI -£2684 to -£4742). The differential QALYs of IDET vs. FRA (adjusted for 
preoperative utilities) were 0.03 (95% CI -0.07 to 0.12). At a willingness-to-pay 
(WTP) threshold of £20,000 per QALY, the net health beneﬁt (NHB) of IDET was 
0.21 and the probability of IDET being cost-effective was 1. If the WTP threshold 
was £30 K/QALY, the NHB was 0.15 (probability cost-effective  0.997). CONCLU-
SIONS: IDET offers a cost-effective alternative to spinal fusion. IDET has the advan-
tage that it is less invasive and can be performed as a day-case procedure.
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OBJECTIVES: . To evaluate the cost-utility of bariatric surgery (gastric bypass, sleeve 
gastrectomy and gastric banding) versus ordinary treatment in health care. METHODS:  
Analysis was done from health care providers’ perspective using a Markov cycle tree 
and a time horizon of ten years. Events during the ﬁrst year, including mortality and 
primary complications resulting in reoperation, were modelled in a decision tree. Then 
the patient cohort moves into a state transition model including four states: alive (no 
reoperation or abdominoplasty), reoperation, abdominoplasty, and death. The param-
eter values were taken from a large representative population survey measuring health-
related quality of life (HRQoL) and health service use, as well as from registers and 
literature. When necessary, expert opinions were used. Different types of sensitivity 
analysis were conducted. RESULTS: . In CUA bariatric surgery dominated strongly 
the ordinary treatment. The mean cost was a31,800 and a44,800 and the mean 
number of QALYs 7.05 and 6.51 for bariatric surgery and ordinary treatment, respec-
tively. Uncertainty around the parameter values was tested comprehensively in sensi-
tivity analyses and the results were robust. CONCLUSIONS: The model takes into 
account all the major events. Strengths of the model include the actual cost data on 
bariatric surgery and inclusion of abdominoplasty, which seems to be neglected in 
previous analyses. Also, a unique set of data on mean health care costs and HRQoL 
for both alternatives was available. The time horizon is rather short and may under-
estimate the effectiveness of bariatric surgery, but it is based on available follow-up 
data.
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OBJECTIVES: To describe and measure intravenous patient controlled analgesia (IV-
PCA) processes in postoperative pain management in patients in clinical practice that 
has undergone surgery at the Uppsala University Hospital, Sweden. METHODS: 
A model was designed and visualized via swimlane notation. Sub process levels 
were deﬁned as “education”, “purchasing/depreciation/maintenance”, “procure-
ment”, “supply”, “application” and “disposal”. Based on these, data was collected 
by two research methods, interviews and measurement forms including patient and 
staff satisfaction questionnaires. RESULTS: Ten members of hospital personnel with 
different responsibilities were interviewed to deﬁne the roles and activities involved in 
the entire IV-PCA process. Ten different roles were deﬁned with 149 different activi-
ties. The involved roles and the duration of each activity in the sub process levels 
“supply”, “application” and “disposal” were measured from 85 consecutive patients 
with 13 different surgery types. The average duration of IV-PCA use per patient was 
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87 hours and 32 minutes. The staff spent on average 85 minutes in IV-PCA related 
activities, of which the nurse spent 98%. The average cost, including material and 
staff, for 24-hour usage of IV-PCA was a58.38. The patients thought that their pain 
was under control and they did not think it could be treated better, but they had some 
problem with pain when breathing or expectorating. According to the staff the IV-PCA 
system was easy to use for the patient but hindered their mobilization. CONCLU-
SIONS: IV-PCA involves many different roles and activities and intertwined sub pro-
cesses. Therefore the whole system is complex and resource demanding. Comparisons 
of the results from similar studies at other hospitals will be very useful when optimiz-
ing the process.
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OBJECTIVES: Sickle cell disease (SCD) is an inherited disorder predominantly affect-
ing people of African descent, and is characterized by the production of defective 
hemoglobin. Patients with SCD may experience intermittent and sometimes life-threat-
ening complications often leading to frequent hospitalizations. Hydroxyurea (HU) is 
the only pharmacologic intervention approved (in 1998) for the treatment of adult 
SCD. This study expands upon previous research (Lanzkron et al, 2006) and generates 
national estimates of changes in SCD-related hospitalization rates and associated 
resource use in the United States (US) following approval of HU. METHODS: Dis-
charge data from the 1996–2005 HCUP Nationwide Inpatient Samples for adult (q20 
years) African American (AA) patients with a primary SCD diagnosis (ICD-9-CM 
codes 282.6, 282.6x) were analyzed. Weighted, age-standardized hospitalization rates, 
and estimates of total charges and length of stay (LOS) were calculated for the 2 years 
before (1996–1997) and 8 years (1998–2005) following approval of HU. RESULTS: 
The age-standardized rate of SCD-related hospitalizations (per 10,000 2008 US adult 
AA population) has fallen appreciably from just before HU’s approval in 1997 to 
2005, from 17.3/10,000 to 13.8/10,000, a reduction of ~20%. During this period, the 
mean LOS has remained roughly unchanged (~6 days), though interestingly, mean 
total charges (in 2008 USD) incurred during an SCD-related stay have increased nearly 
65%, from $15,197 in 1997 to $25,005 in 2005. CONCLUSIONS: We examined 
changes in rates of SCD-related hospitalizations and associated outcomes among AA 
patients following approval of HU for treatment of adult SCD. We observed a general 
decrease in the rate of hospitalizations over the ﬁrst 7 years following approval of 
HU. However, little difference in LOS was seen, and total charges for this patient 
group have increased appreciably for unknown reasons. Clinicians and other decision-
makers should be aware of the impact that HU appears to have on SCD-related inpa-
tient outcomes.
SYSTEMIC DISORDERS/CONDITIONS – Patient-Reported Outcomes 
Studies
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OBJECTIVES: Cognitive and neurologic dysfunction, the most common physiological 
manifestations of hyponatremia, can signiﬁcantly impair individuals’ health-related 
quality of life (HRQOL). Therapeutic correction of hyponatremia should focus not 
only on normalization of serum sodium, but improvement of patients’ functional 
utility as well. We examined the average change in utility scores from initiation of           
either tolvaptan therapy or standard of care (SOC) to day-7 and day-30 post-initiation. 
Standardized utility scores were derived from SF-12 scores from pooled SALT (Study  
of Ascending Levels of Tolvaptan in Hyponatremia) I and II data. METHODS: SF-12 
scores were mapped to the EQ-5D and utility scores were derived using methodology 
developed by Gray, et.al, 2006. Mean change from baseline was assessed for both 
tolvaptan and standard of care (SOC) patient cohorts at day-7 and day-30, quantiﬁed 
as both absolute and percent change. Differences from baseline to day-7 and day-30 
were assessed using a student’s t test. RESULTS: All patients in the SALT trials had 
a baseline serum sodium 135 mEq/L. From baseline to day-7, the mean increase in 
utility score for tolvaptan patients (n  180) was 0.084, compared to an increase of 
0.032 for patients receiving SOC (n  163) (p  0.183). A statistically signiﬁcant mean 
increase in utility was associated with tolvaptan use from baseline to day 30 post-
therapy initiation compared with SOC (p  0.005). The mean increase in utility score 
at day 30 for patients receiving tolvaptan (n  150) was 0.108, whereas utility scores 
for patients receiving SOC (n  164) had returned to baseline values by day-30, with 
a mean change from baseline of 0.001. CONCLUSIONS: Tolvaptan use for hypona-
tremia is associated with an increase in utility compared with SOC, evident at day-7 
and statistically signiﬁcant (p  0.005) at day-30. Utility for tolvaptan patients 
increased from day-7 to day-30 while those for SOC decreased to baseline during this 
period.
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OBJECTIVES: The objective of this study was to measure health state utilities associ-
ated with Immune Thrombocytopenic Purpura (ITP), as perceived by members of the 
Canadian general public. METHODS: An electronic version of the Time Trade-off 
(TTO) method was developed and administered to a sample of the general public in 
Canada. Twelve distinct health states were deﬁned based on severity of bleeding, 
presence of other adverse events, and whether treatment was with romiplostim (a new 
thrombopoietin mimetic agent) or standard of care. Results from two 24-week ran-
domized controlled phase 3 trials were used in developing health state descriptions. 
Pilot surveys were developed to ensure ease of use and to improve measurement 
characteristics of the ﬁnal survey. A sample of 813 subjects was needed for power 
0.90 and an alpha error of 0.05. Utility scores were reported as mean, median and 
range for each health state and compared using Dunn’s post-hoc test. RESULTS: After 
two pilot tests on 126 participants, 821 adults [mean age 36.4 (range 22–80) years, 
63% female] from Ontario, Canada, completed the TTO valuation survey. Mean (SD) 
utility scores ranged from 0.476 (0.271) for the most severe health state describing 
signiﬁcant bleeding to 0.633 (0.282) for the health state depicting successful treatment 
with romiplostim without bleeding. Mean differences between the most severe bleed-
ing health state and 5 other health states were statistically signiﬁcant (p  0.05 for 
each). CONCLUSIONS: The Canadian general public had decreased preference for 
the most severe ITP health states with signiﬁcant bleeding. Respondents most preferred 
ITP health states with no bleeding combined with successful treatment with romip-
lostim. The utility scores derived from these 12 health states can be used as to inform 
cost-effectiveness models of romiplostim as a treatment for ITP in Canada.
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OBJECTIVES: Phenylketonuria (PKU) and its dietary management have a substantial 
effect on quality of life (QOL) of patients and their families. There is little published 
research that quantiﬁes these effects in this orphan disease. The study explores the 
impact of PKU and its severity on QOL by eliciting utilities from a sample of general 
population. METHODS: Health state descriptions were developed for children and 
adults from the literature and expert interviews (n  3) and validated by different clini-
cians (n  3). Health states for children were: controlled (designated by target phenyl-
alanine levels) by diet or medication for severe or mild/moderate disease; uncontrolled 
irrespective of severity. Adults’ states were: controlled by diet or medication; uncon-
trolled. 100 participants across four UK centres were presented randomly with health 
state descriptions which were valued using the EQ-5D questionnaire and TTO (Time-
trade-off) exercise to produce utility values. RESULTS: For both children and adults 
health states, the highest utility was attributed to health states controlled by medicine 
for both the EQ-5D and TTO (Children: severe 0.71–0.91, mild/moderate 0.76–0.94. 
Adults: 0.79–0.83). The uncontrolled state is associated with a lower utility score 
across groups and instruments. The EQ-5D scores were lower compared to TTO 
(particularly for children where parents found difﬁculty in trading off length of life). 
The addition of a drug, adjunct to diet, had larger effect on the EQ-5D score. Utilities 
for children were higher than adults across methods CONCLUSIONS: This small 
study provides evidence of a QoL impact of phenylketonuria. In both TTO and EQ-5D 
valuations, utilities were higher in controlled compared to uncontrolled state in chil-
dren and adults. The addition of an effective drug, adjunct to diet, to control PKU 
improved utility further. This research also provides insight into the difﬁculties mea-
suring utility in orphan diseases where natural history is hard to deﬁne.
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A COMPARATIVE STUDY ON HEMOPHILIA TREATMENT AND 
MEDICATION BY THE PRESENCE OF INHIBITORS IN SOUTH KOREA
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OBJECTIVES: Hemophilia is a rare and intractable disease. Although it is a rare, the 
per-capita cost of the disease covered by health insurance budget is high. The genera-
tion of patients with inhibitors incurs higher expenses and is prone to complications. 
This study compares treatment and medication pattern by the presence of inhibitors. 
METHODS: A survey was conducted for 99 patients without inhibitors and 32 
patients with inhibitors. Age distribution of patients was similar to the actual distribu-
tion of patients. The rate and frequency of hospitalization, treatment-related tests, 
adjuvant treatment and the rate of complications were examined. In addition, patients’ 
age, drugs in use, the number of hospital visits, and the number of drug administration 
